Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors

被引：0
|
作者：
Matsumoto, Koji [1 ]
机构：
[1] Hyogo Canc Ctr, Div Med Oncol, Akashi, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz336
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MS3 - 3
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [2] The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
    Lorusso, Domenica
    Fontanella, Caterina
    Maltese, Giuseppa
    Lepori, Stefano
    Tripodi, Elisa
    Bogani, Giorgio
    Raspagliesi, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 687 - 696
  • [3] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [4] PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?
    Smith, H. J.
    Haygood, C. L. Walters
    Arend, R. C.
    Leath, C. A., III
    Straughn, J. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 9 - 9
  • [5] PARP Inhibitor Rechallenge Could be an Effective Strategy in Platinum-Sensitive Ovarian Cancer: A Retrospective Study
    Zhong, Lin
    Wang, Haixia
    Lei, Cuirong
    Wang, Ling
    Tang, Qin
    Huang, Yiqin
    He, Misi
    Zou, Dongling
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (03): : 2609 - 2619
  • [6] A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China
    Chen, Jinghong
    Zhang, Mengpei
    Li, Kemin
    Duan, Yuanqiong
    Lin, Xiaojuan
    Zhong, Lan
    Li, Qintong
    Yin, Rutie
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [7] PARP INHIBITORS MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER: A COMPREHENSIVE CANCER CENTRE'S EXPERIENCE
    Moreira, I.
    Ferreira, M.
    Lopes, A. R.
    Savva-Bordalo, J.
    Abreu, M.
    Sousa, S.
    Pereira, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A239 - A239
  • [8] Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
    Antonio Lopez-Guerrero, Jose
    Romero, Ignacio
    Poveda, Andres
    CHINESE JOURNAL OF CANCER, 2015, 34 (01) : 41 - 49
  • [9] Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
    Jos Antonio LpezGuerrero
    Ignacio Romero
    Andrs Poveda
    ChineseJournalofCancer, 2015, 34 (01) : 41 - 49
  • [10] Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer
    Hanker, L.
    Valentine, M. C.
    Perhanidis, J. A.
    Hawkes, C.
    Thaker, P. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 241 - 241
12345